Pharmafile Logo

News and Press Releases

FASENRA​ approved in ​US​ for ​hypereosinophilic syndrome​

14 May 2026 -- Cambridge, UK -- AstraZeneca’s FASENRA (benralizumab) has been approved by the US FDA for the treatment of adult and pediatric patients aged 12 years and older with...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 14, 2026

Chiesi Receives MHRA Approval for Additional Dosing Regimen of Elfabrio (pegunigalsidase alfa) 2mg/kg administered every-four-weeks in adults stable with an enzyme replacement therapy

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an additional dosing regimen of 2mg/kg administered every-four-weeks for pegunigalsidase alfa in adults stable with an enzyme replacement therapy...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 14, 2026

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

AOP Health and VRG Therapeutics Enter Co-Development Partnership for New Immunology Program

12 May 2026 -- Vienna, Austria and Budapest, Hungary -- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026

AOP Pharma
office@aoporphan.com
Leopold-Ungar-Platz 2 1190 Vienna, Austria

IMAAVY (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE)...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Moderna Receives MHRA Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

The LP.8.1 vaccine is the first commercially licenced mRNA vaccine to be manufactured in the UK at the Moderna Innovation and Technology Centre in Oxfordshire The updated vaccines will be...

Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2026

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

New collaborative strategy platform launches to empower biopharma teams to reach peak sales faster and with greater confidence

11 November 2025 -- London, UK -- In a drug development landscape defined by shifting policies, geopolitical uncertainty, and increasing competitive pressure, a new collaborative strategy platform, Nmblr, has launched to empower...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: November 11, 2025

Nmblr

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

3 November 2025 -- Massachusetts, US -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced three presentations of new preclinical data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 3, 2025

Tessera Therapeutics
101 South St, Somerville, MA 02143, United States

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025 10 October 2025 -- Paris, France and Lund, Sweden -- Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

Genethon
1 bis, rue de l’Internationale 91000 EVRY-COURCOURONNES

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

Terumo Blood and Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America  

Regulatory approvals in 14 countries expand treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis Approvals align with the historic World Health Assembly resolution on rare diseases. 16...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: September 16, 2025

Terumo Blood and Cell Technologies
Old Belfast Road Millbrook Larne BT40 2SH

Terumo BCT and PwC Belgium Join Forces to Break Barriers in Access to Advanced Cell and Gene Therapies 

2 September 2025 -- Brussels, Belgium -- Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, and PwC Belgium today announce a new collaboration focused on driving equitable...

Category: Biotechnology, Drug Discovery, Logistics, Manufacturing and Packing
Posted: September 8, 2025

Terumo Blood and Cell Technologies
Old Belfast Road Millbrook Larne BT40 2SH

Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase Up...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 8, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia.  3 April...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 3, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

MedExecWomen Hosts 6th Annual Conference to Discuss Future of Medtech Industry

18 March 2025 -- Massachusetts, US -- MedExecWomen, a non-profit organization focused on empowering executive women in medtech to accelerate the positive impact of medical devices, diagnostics, drug delivery, and...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 18, 2025

MedExecWomen
pr@scorrmarketing.com

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy

Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX...

Category: Biotechnology, Clinical Trials, Other
Posted: February 25, 2025

ONWARD Medical
investors@onwd.com
Schimmelt 2. 5656 AE, Eindhoven, the Netherlands